About Us

We are a young, enthusiastic company that aims to change the way clinical trials are designed and performed, transforming drug development and production and ultimately improving the health and quality of life.

Learn More

Solution

Panacea-ml delivers high-value insights that enable pharmaceutical companies and CROs to design and perform clinical trials that can bring effective treatments to market faster

Pharma

Minimize the risk of trial failure.

Reduce trial duration.

Reduce trial cost.

Maximize the chances for market approval.

CRO

Advantage over competition.

Reduce operational costs.

Increase recruitment rates.

Reduce dropout.

Product

Our SaaS AI system has a user-friendly interface customized to the client and is agnostic to both the disease and the treatment. Currently, we validate our products in diseases including ALS, diabetes, and cancer, among others.

Book a demo

Mission

We leverage clinical development data analytics to streamline clinical trials, providing drug developers and CROs with a competitive edge. Panacea-ml's analysis of historical patient data identifies which trial participants could most benefit from a drug and which might develop adverse side effects, increasing the chances of a successful trial and improving patient care and outcomes.
Panacea-ml produces valuable insights, which help our clients make informed decisions.

Naomi Fried, Ph.D
PharmStars CEO

I endorse Panacea-ml's innovative explainable-AI technology for revolutionizing trial design, improving insights into failed trials, and enforcing the probability of success in clinical programs.

Julian Isla
Microsoft Data and AI Manager

EMA COMP Member

I'm impressed by Panacea-ml's use of advanced analytics and explainable-AI to optimize patient selection and enhance trial outcomes with unique insights. Their approach makes trials more efficient and patient-centric.

image001 (1)_edited_edited_edited_edited.jpg

Ed Saltzman
Lumanity Senior Strategic Advisor

I believe Panacea-ml's innovative technology will reduce clinical trial attrition, accelerating patient access to treatments, while maximizing return from clinical development spend.